L1CAM and glioblastoma: Similarly, in glioblastoma, L1CAM promotes self-renewal and confers temozolomide resistance by maintaining neural stem cell-like properties [5,6], whereas in endometrial cancer, it contributes to the formation of cancer initiating cells and resistance to paclitaxel by activating EMT-associated pathways [7].